◆英語タイトル:Epizyme Inc (EPZM) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C5337
◆発行会社(調査会社):
GlobalData
◆発行日:2018年9月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Epizyme Inc (EPZM) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Epizyme, Inc. (Epizyme) is a biopharmaceutical company that develops novel epigenetic therapies for the treatment of cancer and other disorders. The company discovers and develops small molecule inhibitors of a class of enzymes, namely, histone methyl transferases (HMTs) and other chromatin modifying proteins (CMPs). Using its proprietary platform and collaborations, the company has initiated the identification and development of small molecule inhibitors of CMPs and HMTs. The company is developing product candidates for the treatment of solid tumors, non-hodgins lymphoma, mesothelioma, ovarian cancer, molecularly targeted tumors and sickle cell disease. Epizyme is headquartered in Cambridge, Massachusetts, the US.
Epizyme Inc Key Recent Developments
Aug 02,2018: Epizyme reports second quarter 2018 financial results and provides business updates
Jul 23,2018: Epizyme names Dr. Shefali Agarwal as Chief Medical Officer
May 08,2018: Epizyme Reports First Quarter 2018 Financial Results and Provides Business Updates
Mar 13,2018: Epizyme Reports Fourth Quarter and Full Year 2017 Financial Results
Mar 12,2018: Epizyme Appoints Oncology Industry Leader Michael Giordano, M.D., to its Board of Directors
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Epizyme Inc – Key Facts 6
Epizyme Inc – Key Employees 7
Epizyme Inc – Key Employee Biographies 8
Epizyme Inc – Major Products and Services 9
Epizyme Inc – History 10
Epizyme Inc – Company Statement 12
Epizyme Inc – Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Section 2 – Company Analysis 15
Company Overview 15
Epizyme Inc – Business Description 16
R&D Overview 16
Epizyme Inc – Corporate Strategy 17
Epizyme Inc – SWOT Analysis 18
SWOT Analysis – Overview 18
Epizyme Inc – Strengths 18
Epizyme Inc – Weaknesses 19
Epizyme Inc – Opportunities 20
Epizyme Inc – Threats 21
Epizyme Inc – Key Competitors 22
Section 3 – Company Financial Ratios 23
Financial Ratios – Capital Market Ratios 23
Financial Ratios – Annual Ratios 24
Performance Chart 26
Financial Performance 26
Financial Ratios – Interim Ratios 27
Financial Ratios – Ratio Charts 28
Section 4 – Company’s Lifesciences Financial Deals and Alliances 29
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30
Epizyme Inc, Recent Deals Summary 31
Section 5 – Company’s Recent Developments 32
Aug 02, 2018: Epizyme reports second quarter 2018 financial results and provides business updates 32
May 08, 2018: Epizyme Reports First Quarter 2018 Financial Results and Provides Business Updates 34
Mar 12, 2018: Epizyme Appoints Oncology Industry Leader Michael Giordano, M.D., to its Board of Directors 36
Nov 01, 2017: Epizyme Reports Third Quarter 2017 Operating Results and Company Updates 37
Aug 15, 2017: Epizyme Announces Leadership Transition for Finance Organization 38
Aug 04, 2017: Epizyme Reports Second Quarter 2017 Financial Results and Clinical and Business Progress 39
May 08, 2017: Epizyme Reports First Quarter 2017 Results and Provides Corporate Update 41
Mar 09, 2017: Epizyme Reports 2016 Financial Results and Provides 2017 Pipeline Goals 42
Mar 09, 2017: Epizyme President of Research and Chief Scientific Officer, Robert Copeland, Announces Retirement from the Company 44
Feb 07, 2017: Epizyme Elects Kevin Conroy to its Board of Directors 45
Section 6 – Appendix 46
Methodology 46
Ratio Definitions 46
About GlobalData 50
Contact Us 50
Disclaimer 50
List of Tables
Epizyme Inc, Key Facts 6
Epizyme Inc, Key Employees 7
Epizyme Inc, Key Employee Biographies 8
Epizyme Inc, Major Products and Services 9
Epizyme Inc, History 10
Epizyme Inc, Subsidiaries 14
Epizyme Inc, Key Competitors 22
Epizyme Inc, Ratios based on current share price 23
Epizyme Inc, Annual Ratios 24
Epizyme Inc, Annual Ratios (Cont...1) 25
Epizyme Inc, Interim Ratios 27
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30
Epizyme Inc, Recent Deals Summary 31
Currency Codes 46
Capital Market Ratios 46
Equity Ratios 47
Profitability Ratios 47
Cost Ratios 48
Liquidity Ratios 48
Leverage Ratios 49
Efficiency Ratios 49
List of Figures
Epizyme Inc, Performance Chart (2013 - 2017) 26
Epizyme Inc, Ratio Charts 28
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29
Epizyme Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 30